RE: Transgenic mouse models support a protective role of type I IFN response in SARS-CoV-2 infection- related lung immunopathology and neuroinvasion16 Dec 2023 21:28
From the interim results, September:
The Company's cash resources are sufficient to cover its plans to design and establish data from an observational study and two investigator-led/Synairgen-sponsored Phase 2 clinical trials, including manufacture of active and placebo for use in these trials. Regardless of the outcome of these activities, which are uncertain, the Company's available resources are sufficient to cover existing committed costs and the estimated costs of these activities until at least 30 September 2024, being a period of at least twelve months from the date of this report and, for this reason, the financial statements have been prepared on a going concern basis.